Avita Medical Inc. (NASDAQ: RCEL) Stock Competitors & Peer Comparison
See RCEL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RCEL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RCEL | $10.94 | +1.67% | 271.8M | -7.60 | -$1.44 | N/A |
| ABT | $108.79 | -1.52% | 188.2B | 20.88 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $93.10 | +1.00% | 119.2B | 16.84 | $5.53 | +3.08% |
| SYK | $307.99 | -1.35% | 118.1B | 23.00 | $13.39 | +1.13% |
| BSX | $46.95 | -2.94% | 69.8B | 15.15 | $3.10 | N/A |
| EW | $89.78 | -1.15% | 51.7B | 33.25 | $2.70 | N/A |
| DXCM | $89.71 | +0.02% | 33.9B | 35.18 | $2.55 | N/A |
| GEHC | $69.72 | -1.19% | 31.5B | 15.29 | $4.56 | +0.20% |
| PHG | $26.05 | -1.21% | 25.5B | 14.88 | $1.75 | +3.80% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
RCEL vs ABT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ABT has a market cap of 188.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ABT trades at $108.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ABT's P/E ratio is 20.88. In terms of profitability, RCEL's ROE is +2.32%, compared to ABT's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
RCEL vs BSX-PA Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RCEL's ROE is +2.32%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
RCEL vs MDT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, MDT has a market cap of 119.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while MDT trades at $93.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas MDT's P/E ratio is 16.84. In terms of profitability, RCEL's ROE is +2.32%, compared to MDT's ROE of +0.14%. Regarding short-term risk, RCEL is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
RCEL vs SYK Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SYK has a market cap of 118.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SYK trades at $307.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SYK's P/E ratio is 23.00. In terms of profitability, RCEL's ROE is +2.32%, compared to SYK's ROE of +0.16%. Regarding short-term risk, RCEL is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
RCEL vs BSX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BSX has a market cap of 69.8B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BSX trades at $46.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BSX's P/E ratio is 15.15. In terms of profitability, RCEL's ROE is +2.32%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RCEL is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
RCEL vs EW Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while EW trades at $89.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas EW's P/E ratio is 33.25. In terms of profitability, RCEL's ROE is +2.32%, compared to EW's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
RCEL vs DXCM Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, DXCM has a market cap of 33.9B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while DXCM trades at $89.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas DXCM's P/E ratio is 35.18. In terms of profitability, RCEL's ROE is +2.32%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, RCEL is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
RCEL vs GEHC Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while GEHC trades at $69.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas GEHC's P/E ratio is 15.29. In terms of profitability, RCEL's ROE is +2.32%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
RCEL vs PHG Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PHG trades at $26.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PHG's P/E ratio is 14.88. In terms of profitability, RCEL's ROE is +2.32%, compared to PHG's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
RCEL vs ZBH Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ZBH trades at $98.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ZBH's P/E ratio is 11.67. In terms of profitability, RCEL's ROE is +2.32%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RCEL is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
RCEL vs ABMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RCEL's ROE is +2.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
RCEL vs PEN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PEN trades at $321.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PEN's P/E ratio is 83.90. In terms of profitability, RCEL's ROE is +2.32%, compared to PEN's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
RCEL vs SWAV Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RCEL's ROE is +2.32%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RCEL is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
RCEL vs SNN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SNN trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SNN's P/E ratio is 13.50. In terms of profitability, RCEL's ROE is +2.32%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RCEL is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
RCEL vs ALGN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ALGN trades at $159.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ALGN's P/E ratio is 14.57. In terms of profitability, RCEL's ROE is +2.32%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, RCEL is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ALGN's competition here
Glaukos Corporation (NYSE: GKOS)
RCEL vs GKOS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while GKOS trades at $180.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas GKOS's P/E ratio is -209.80. In terms of profitability, RCEL's ROE is +2.32%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, RCEL is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check GKOS's competition here
Globus Medical, Inc. (NYSE: GMED)
RCEL vs GMED Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while GMED trades at $78.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas GMED's P/E ratio is 17.59. In terms of profitability, RCEL's ROE is +2.32%, compared to GMED's ROE of +0.12%. Regarding short-term risk, RCEL is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check GMED's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
RCEL vs BIO Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BIO trades at $387.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BIO's P/E ratio is 41.79. In terms of profitability, RCEL's ROE is +2.32%, compared to BIO's ROE of +0.03%. Regarding short-term risk, RCEL is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
RCEL vs BIO-B Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, RCEL's ROE is +2.32%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, RCEL is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
RCEL vs PODD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PODD trades at $150.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PODD's P/E ratio is 25.65. In terms of profitability, RCEL's ROE is +2.32%, compared to PODD's ROE of +0.27%. Regarding short-term risk, RCEL is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
RCEL vs MASI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas MASI's P/E ratio is 44.43. In terms of profitability, RCEL's ROE is +2.32%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RCEL is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
RCEL vs BRKR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BRKR trades at $59.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BRKR's P/E ratio is 29.85. In terms of profitability, RCEL's ROE is +2.32%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, RCEL is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
RCEL vs BRKRP Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BRKRP trades at $438.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BRKRP's P/E ratio is 238.04. In terms of profitability, RCEL's ROE is +2.32%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, RCEL is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
RCEL vs NARI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NARI's P/E ratio is -59.24. In terms of profitability, RCEL's ROE is +2.32%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RCEL is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
RCEL vs HAE Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while HAE trades at $102.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas HAE's P/E ratio is 20.52. In terms of profitability, RCEL's ROE is +2.32%, compared to HAE's ROE of +0.11%. Regarding short-term risk, RCEL is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
RCEL vs LIVN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while LIVN trades at $81.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas LIVN's P/E ratio is 19.29. In terms of profitability, RCEL's ROE is +2.32%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
RCEL vs ITGR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ITGR trades at $125.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ITGR's P/E ratio is 19.76. In terms of profitability, RCEL's ROE is +2.32%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, RCEL is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
RCEL vs IRTC Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while IRTC trades at $123.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas IRTC's P/E ratio is -287.05. In terms of profitability, RCEL's ROE is +2.32%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, RCEL is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
RCEL vs AXNX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RCEL's ROE is +2.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RCEL is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
RCEL vs TMDX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while TMDX trades at $86.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas TMDX's P/E ratio is 44.15. In terms of profitability, RCEL's ROE is +2.32%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, RCEL is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
RCEL vs NEOG Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NEOG trades at $11.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NEOG's P/E ratio is 41.57. In terms of profitability, RCEL's ROE is +2.32%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, RCEL is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
RCEL vs AXGN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AXGN trades at $47.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AXGN's P/E ratio is 123.95. In terms of profitability, RCEL's ROE is +2.32%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, RCEL is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
RCEL vs UFPT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while UFPT trades at $286.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas UFPT's P/E ratio is 29.27. In terms of profitability, RCEL's ROE is +2.32%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RCEL is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
RCEL vs ESTA Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ESTA trades at $72.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ESTA's P/E ratio is -57.38. In terms of profitability, RCEL's ROE is +2.32%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, RCEL is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
RCEL vs NUVA Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RCEL's ROE is +2.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RCEL is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
RCEL vs NVCR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NVCR trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NVCR's P/E ratio is -13.57. In terms of profitability, RCEL's ROE is +2.32%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, RCEL is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check NVCR's competition here
Butterfly Network, Inc. (NYSE: BFLY)
RCEL vs BFLY Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BFLY trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BFLY's P/E ratio is -30.35. In terms of profitability, RCEL's ROE is +2.32%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, RCEL is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
RCEL vs INSP Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while INSP trades at $62.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas INSP's P/E ratio is 27.34. In terms of profitability, RCEL's ROE is +2.32%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RCEL is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
RCEL vs CNMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CNMD trades at $49.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CNMD's P/E ratio is 10.84. In terms of profitability, RCEL's ROE is +2.32%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, RCEL is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
RCEL vs ATEC Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ATEC trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ATEC's P/E ratio is -155.50. In terms of profitability, RCEL's ROE is +2.32%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, RCEL is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
RCEL vs TNDM Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while TNDM trades at $20.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas TNDM's P/E ratio is -21.97. In terms of profitability, RCEL's ROE is +2.32%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, RCEL is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
RCEL vs HSKA Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RCEL's ROE is +2.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RCEL is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
RCEL vs IART Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while IART trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas IART's P/E ratio is 6.97. In terms of profitability, RCEL's ROE is +2.32%, compared to IART's ROE of -0.01%. Regarding short-term risk, RCEL is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
RCEL vs AORT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AORT trades at $25.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AORT's P/E ratio is 42.67. In terms of profitability, RCEL's ROE is +2.32%, compared to AORT's ROE of -0.01%. Regarding short-term risk, RCEL is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
RCEL vs PRCT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PRCT trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PRCT's P/E ratio is -11.02. In terms of profitability, RCEL's ROE is +2.32%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, RCEL is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
RCEL vs AVNS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AVNS's P/E ratio is 27.77. In terms of profitability, RCEL's ROE is +2.32%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RCEL is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
RCEL vs LMRI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while LMRI trades at $11.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas LMRI's P/E ratio is -23.15. In terms of profitability, RCEL's ROE is +2.32%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, RCEL is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
RCEL vs SILK Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SILK's P/E ratio is -18.96. In terms of profitability, RCEL's ROE is +2.32%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SILK's competition here
Enovis Corporation (NYSE: ENOV)
RCEL vs ENOV Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ENOV trades at $19.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ENOV's P/E ratio is 5.55. In terms of profitability, RCEL's ROE is +2.32%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, RCEL is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check ENOV's competition here
IRadimed Corporation (NASDAQ: IRMD)
RCEL vs IRMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while IRMD trades at $86.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas IRMD's P/E ratio is 43.51. In terms of profitability, RCEL's ROE is +2.32%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, RCEL is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
RCEL vs FNA Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas FNA's P/E ratio is -19.83. In terms of profitability, RCEL's ROE is +2.32%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RCEL is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
RCEL vs BVS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BVS has a market cap of 972.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BVS trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BVS's P/E ratio is 18.89. In terms of profitability, RCEL's ROE is +2.32%, compared to BVS's ROE of +0.28%. Regarding short-term risk, RCEL is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
RCEL vs CBLL Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CBLL has a market cap of 932.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CBLL trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CBLL's P/E ratio is -13.96. In terms of profitability, RCEL's ROE is +2.32%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, RCEL is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check CBLL's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
RCEL vs BBNX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BBNX has a market cap of 896.2M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BBNX trades at $19.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BBNX's P/E ratio is -12.07. In terms of profitability, RCEL's ROE is +2.32%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, RCEL is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BBNX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
RCEL vs AHCO Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AHCO has a market cap of 873.5M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AHCO trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AHCO's P/E ratio is 13.10. In terms of profitability, RCEL's ROE is +2.32%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, RCEL is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
RCEL vs INMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, INMD has a market cap of 853M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while INMD trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas INMD's P/E ratio is 10.31. In terms of profitability, RCEL's ROE is +2.32%, compared to INMD's ROE of +0.12%. Regarding short-term risk, RCEL is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
RCEL vs AVR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, AVR has a market cap of 847.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while AVR trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas AVR's P/E ratio is -4.49. In terms of profitability, RCEL's ROE is +2.32%, compared to AVR's ROE of -0.78%. Regarding short-term risk, RCEL is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
RCEL vs CSII Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CSII's P/E ratio is -20.83. In terms of profitability, RCEL's ROE is +2.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RCEL is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
RCEL vs SIBN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SIBN has a market cap of 826.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SIBN trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SIBN's P/E ratio is -54.82. In terms of profitability, RCEL's ROE is +2.32%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, RCEL is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
RCEL vs VREX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, VREX has a market cap of 779.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while VREX trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas VREX's P/E ratio is 19.49. In terms of profitability, RCEL's ROE is +2.32%, compared to VREX's ROE of +0.05%. Regarding short-term risk, RCEL is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
RCEL vs SSII Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SSII has a market cap of 678.4M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SSII trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SSII's P/E ratio is -66.12. In terms of profitability, RCEL's ROE is +2.32%, compared to SSII's ROE of -0.27%. Regarding short-term risk, RCEL is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
RCEL vs SRDX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RCEL's ROE is +2.32%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, RCEL is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
RCEL vs CTKB Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CTKB trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CTKB's P/E ratio is -24.90. In terms of profitability, RCEL's ROE is +2.32%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, RCEL is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check CTKB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
RCEL vs KIDS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, KIDS has a market cap of 580.2M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while KIDS trades at $22.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas KIDS's P/E ratio is -19.14. In terms of profitability, RCEL's ROE is +2.32%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, RCEL is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
RCEL vs APEN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas APEN's P/E ratio is -9.43. In terms of profitability, RCEL's ROE is +2.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RCEL is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
RCEL vs DCTH Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while DCTH trades at $16.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, RCEL's ROE is +2.32%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, RCEL is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
RCEL vs ZIMV Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RCEL's ROE is +2.32%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, RCEL is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
RCEL vs CERS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CERS has a market cap of 517.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CERS trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CERS's P/E ratio is -51.30. In terms of profitability, RCEL's ROE is +2.32%, compared to CERS's ROE of -0.10%. Regarding short-term risk, RCEL is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
RCEL vs NPCE Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NPCE has a market cap of 502.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NPCE trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NPCE's P/E ratio is -25.88. In terms of profitability, RCEL's ROE is +2.32%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, RCEL is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
RCEL vs TCMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, TCMD has a market cap of 496.5M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while TCMD trades at $22.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas TCMD's P/E ratio is 20.38. In terms of profitability, RCEL's ROE is +2.32%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, RCEL is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
RCEL vs SGHT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SGHT has a market cap of 456M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SGHT trades at $8.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SGHT's P/E ratio is -14.96. In terms of profitability, RCEL's ROE is +2.32%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, RCEL is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
RCEL vs CARL Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CARL has a market cap of 421.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CARL trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CARL's P/E ratio is -10.85. In terms of profitability, RCEL's ROE is +2.32%, compared to CARL's ROE of -0.38%. Regarding short-term risk, RCEL is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check CARL's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
RCEL vs CLPT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CLPT has a market cap of 421.4M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CLPT trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CLPT's P/E ratio is -11.91. In terms of profitability, RCEL's ROE is +2.32%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, RCEL is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
RCEL vs SENS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SENS has a market cap of 413.8M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SENS trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SENS's P/E ratio is -4.44. In terms of profitability, RCEL's ROE is +2.32%, compared to SENS's ROE of -1.66%. Regarding short-term risk, RCEL is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check SENS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
RCEL vs PACB Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PACB has a market cap of 403.8M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PACB trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PACB's P/E ratio is -3.17. In terms of profitability, RCEL's ROE is +2.32%, compared to PACB's ROE of -49.62%. Regarding short-term risk, RCEL is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check PACB's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
RCEL vs OFIX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, OFIX has a market cap of 376.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while OFIX trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas OFIX's P/E ratio is -6.06. In terms of profitability, RCEL's ROE is +2.32%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, RCEL is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
RCEL vs CATX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CATX has a market cap of 354.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CATX trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CATX's P/E ratio is -2.34. In terms of profitability, RCEL's ROE is +2.32%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RCEL is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
RCEL vs TMCI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, TMCI has a market cap of 316.6M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while TMCI trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas TMCI's P/E ratio is -5.19. In terms of profitability, RCEL's ROE is +2.32%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, RCEL is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
RCEL vs SMLR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RCEL's ROE is +2.32%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, RCEL is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
RCEL vs TLSI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, TLSI has a market cap of 306.6M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while TLSI trades at $4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas TLSI's P/E ratio is -2.96. In terms of profitability, RCEL's ROE is +2.32%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, RCEL is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
RCEL vs CV Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, CV has a market cap of 298.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while CV trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas CV's P/E ratio is -2.39. In terms of profitability, RCEL's ROE is +2.32%, compared to CV's ROE of -1.78%. Regarding short-term risk, RCEL is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check CV's competition here
RxSight, Inc. (NASDAQ: RXST)
RCEL vs RXST Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, RXST has a market cap of 270.7M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while RXST trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas RXST's P/E ratio is -5.79. In terms of profitability, RCEL's ROE is +2.32%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RCEL is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
RCEL vs PROF Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, PROF has a market cap of 247.1M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while PROF trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas PROF's P/E ratio is -6.94. In terms of profitability, RCEL's ROE is +2.32%, compared to PROF's ROE of -0.56%. Regarding short-term risk, RCEL is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
RCEL vs INFU Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, INFU has a market cap of 245.4M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while INFU trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas INFU's P/E ratio is 29.66. In terms of profitability, RCEL's ROE is +2.32%, compared to INFU's ROE of +0.15%. Regarding short-term risk, RCEL is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
RCEL vs MGRM Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas MGRM's P/E ratio is -12.00. In terms of profitability, RCEL's ROE is +2.32%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, RCEL is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
RCEL vs ELMD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ELMD has a market cap of 228.4M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ELMD trades at $27.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ELMD's P/E ratio is 21.06. In terms of profitability, RCEL's ROE is +2.32%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, RCEL is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
RCEL vs NVRO Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RCEL's ROE is +2.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RCEL is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check NVRO's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
RCEL vs BSGM Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RCEL's ROE is +2.32%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, RCEL is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check BSGM's competition here
Neuronetics, Inc. (NASDAQ: STIM)
RCEL vs STIM Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, STIM has a market cap of 189.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while STIM trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas STIM's P/E ratio is -6.18. In terms of profitability, RCEL's ROE is +2.32%, compared to STIM's ROE of -1.51%. Regarding short-term risk, RCEL is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check STIM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
RCEL vs LUCD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, LUCD has a market cap of 181.5M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while LUCD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas LUCD's P/E ratio is -2.57. In terms of profitability, RCEL's ROE is +2.32%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, RCEL is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
RCEL vs MDGS Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RCEL's ROE is +2.32%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RCEL is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
RCEL vs QIPT Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RCEL's ROE is +2.32%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RCEL is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
RCEL vs FOCL Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while FOCL trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas FOCL's P/E ratio is -4.03. In terms of profitability, RCEL's ROE is +2.32%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, RCEL is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
RCEL vs QSI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, QSI has a market cap of 153.1M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while QSI trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas QSI's P/E ratio is -1.68. In terms of profitability, RCEL's ROE is +2.32%, compared to QSI's ROE of -0.47%. Regarding short-term risk, RCEL is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
RCEL vs INGN Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, INGN has a market cap of 147.6M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while INGN trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas INGN's P/E ratio is -5.99. In terms of profitability, RCEL's ROE is +2.32%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RCEL is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
RCEL vs QTRX Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, QTRX has a market cap of 121.5M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while QTRX trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas QTRX's P/E ratio is -1.02. In terms of profitability, RCEL's ROE is +2.32%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, RCEL is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for RCEL.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
RCEL vs ICAD Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas ICAD's P/E ratio is -20.37. In terms of profitability, RCEL's ROE is +2.32%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, RCEL is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
RCEL vs LNSR Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, LNSR has a market cap of 101.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while LNSR trades at $8.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas LNSR's P/E ratio is 8.42. In terms of profitability, RCEL's ROE is +2.32%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, RCEL is more volatile compared to LNSR. This indicates higher risk in terms of short-term price fluctuations for RCEL.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
RCEL vs HJLI Comparison September 2026
Avita Medical Inc. (NASDAQ: RCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RCEL stands at 271.8M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, RCEL is priced at $10.94 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RCEL currently has a P/E ratio of -7.60, whereas HJLI's P/E ratio is N/A. In terms of profitability, RCEL's ROE is +2.32%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, RCEL is similarly volatile compared to HJLI. This indicates similar risk in terms of short-term price fluctuations for RCEL.Check HJLI's competition here